**Table S1. Unadjusted efficacy outcome measures in patients with or without enthesitis at baseline**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | | **With enthesitis at baseline** | | | **Without enthesitis at baseline** | | |
| **Outcome Measures** | **Week** | **SEC 300 mg**  **(N=144)** | **SEC 150 mg**  **(N=159)** | **PBO**  **(N=163)** | **SEC 300 mg**  **(N=95)** | **SEC 150 mg**  **(N=79)** | **PBO**  **(N=72)** |
| **ACR20a,b** | **16** | 53.5 | 46.5 | 19.6 | 53.7 | 64.6 | 18.1 |
| **104** | 56.8 | 52.4 | – | 62.6 | 62.9 | – |
| **ACR50a,b** | **16** | 31.3 | 21.4 | 6.7 | 35.8 | 35.4 | 5.6 |
| **104** | 44.7 | 24.8 | – | 47.3 | 34.3 | – |
| **ACR70a,b** | **16** | 16.0 | 8.2 | 1.8 | 21.1 | 16.5 | 1.4 |
| **104** | 26.5 | 15.2 | – | 34.1 | 21.4 | – |
| **PASI 90a,c** | **16** | 50.0 | 36.6 | 7.9 | 42.1 | 37.0 | 6.7 |
| **104** | 67.9 | 59.7 | – | 73.5 | 44.4 | – |
| **PASI 75a,c** | **16** | 78.8 | 59.8 | 11.1 | 65.8 | 56.5 | 6.7 |
| **104** | 76.8 | 77.4 | – | 91.2 | 66.7 | – |
| **HAQ-DId** | **16** | −0.5 | −0.3 | −0.2 | −0.5 | −0.5 | −0.2 |
| **104** | −0.5 | −0.4 | – | −0.5 | −0.6 | – |
| **SF-36 PCSd** | **16** | 6.4 | 3.7 | 2.5 | 6.5 | 7.4 | 2.6 |
| **104** | 7.4 | 4.3 | – | 6.6 | 6.9 | – |
| **DAS28-CRPd** | **16** | −1.5 | −1.0 | −0.5 | −1.4 | −1.6 | −0.5 |
| **104** | −1.7 | −1.6 | – | −2.0 | −1.9 | – |
| aResponse, %  bAt Week 16/104, n=144/132 (secukinumab 300 mg), 159/145 (secukinumab 150 mg) and 163 (placebo) with enthesitis and n=95/91 (secukinumab 300 mg), 79/70 (secukinumab 150 mg) and 72 (placebo) without enthesitis at baseline  cAt Week 16/104, n=66/56 (secukinumab 300 mg), 82/62 (secukinumab 150 mg) and 63 (placebo) with enthesitis and n=38/34 (secukinumab 300 mg), 46/36 (secukinumab 150 mg) and 30 (placebo) without enthesitis at baseline (psoriasis subset)  dLS mean change from baseline  ACR, American College of Rheumatology; DAS28-CRP; Disease activity score 28-joint count using C-reactive protein; HAQ-DI, Health assessment questionnaire disability index; LS, least square; n, number of evaluable patients; N, total number of patients; PASI, Psoriasis Area and Severity Index; PBO, placebo; SEC, secukinumab; SF-36 PCS, Short Form 36 Physical Component Summary score | | | | | | | |